{
    "clinical_study": {
        "@rank": "55396", 
        "arm_group": {
            "arm_group_label": "Retrieval and Cryopreservation", 
            "arm_group_type": "Experimental", 
            "description": "Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to retrieve and cryopreserve ovarian tissue from females\n      undergoing a treatment that may lead to irreversible loss of ovarian function."
        }, 
        "brief_title": "Ovarian Tissue Cryopreservation in Females Undergoing Procedures That Will Potentially Lead To Loss of Ovarian Function", 
        "completion_date": {
            "#text": "December 2041", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cancer", 
            "Effects of Chemotherapy", 
            "Unspecified Complication of Bone Marrow Transplant", 
            "Auto Immune Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Autoimmune Diseases", 
                "Immune System Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The aim of this preliminary study is to retrieve and properly cryopreserve ovarian tissue\n      for autotransplantation in any premenopausal female whose ovarian function is threatened in\n      a physiological, pathological or iatrogenic manner in an effort to observe the return of\n      ovarian endocrine function and development of egg(s) appropriate for use in in vitro\n      fertilization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must be female.\n\n          -  Patient must have a disease process where the disease or its treatment      adversely\n             affects ovarian function.\n\n          -  Patient must be recommended for this study by their oncologist or specialist.\n\n          -  Patient (or legally authorized representative) must sign an informed consent.\n\n        Exclusion Criteria:\n\n          -  Patients cannot be male.\n\n          -  Patients must not be HIV positive.\n\n          -  Patient cannot have a poor diagnosis such that she is not expected to survive to\n             adulthood.\n\n          -  Patient cannot have any medical condition that would contraindicate surgery.\n\n          -  Patient cannot have any medical condition that would contraindicate general\n             anesthesia.\n\n          -  Patient cannot have any medical condition that would contraindicate pregnancy."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993732", 
            "org_study_id": "126204"
        }, 
        "intervention": {
            "arm_group_label": "Retrieval and Cryopreservation", 
            "description": "Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.", 
            "intervention_name": "Retrieval and Cryopreservation", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cancer", 
            "Cryopreservation", 
            "Ovarian Function", 
            "In Vitro"
        ], 
        "lastchanged_date": "November 19, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Froedtert and The Medical College of Wisconsin"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53226"
                    }, 
                    "name": "Children's Hospital of Wisconsin"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Ovarian Tissue Cryopreservation As A Means Of Preserving Ovarian Function in Females Undergoing Therapeutic Procedures That Will Potentially Lead To The Irreversible Loss of Ovarian Function", 
        "overall_official": {
            "affiliation": "Medical College of Wisconsin", 
            "last_name": "Estil Strawn, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2041", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Return of hormones produced by the ovarian tissue", 
            "safety_issue": "No", 
            "time_frame": "3 months after re-implantation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993732"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medical College of Wisconsin", 
            "investigator_full_name": "Estil Strawn", 
            "investigator_title": "Professor, Director of Division of Reproductive Endocrinology and Infertility", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Development of egg(s) appropriate for use in in vitro fertilization", 
            "safety_issue": "No", 
            "time_frame": "Participants will be followed through their reproductive years (until the patient reaches 45 years of age)"
        }, 
        "source": "Medical College of Wisconsin", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical College of Wisconsin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2003", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}